During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ...

During a live event, Daniel M. Geynisman, MD, and participants discussed their answers to a poll on which combination to use ...

The flywheel for building, design and technology innovation. That is TKI Construction and Technology. By enabling industry, knowledge institutions, government ministries and umbrella organisations to ...

Data suggest that taletrectinib “provides clinically meaningful tumor shrinkage and prolonged disease control as a treatment option for advanced ROS1+ NSCLC, regardless of treatment history,” ...

La Niña comes to an end, so now what happens to the weather? Here's what the second half of spring could look like in Canada ...